To investigate the conditional context between bcr-abl breakpoint variant (b3a2 or b2a2), IM therapy and acquisition of ACA and clonal evolution we have analyzed therapy-related acquisition of ACA in 1151 patients under IM treatment that were randomized to the CML-Study IV. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.